跳至主要内容
临床试验/NCT00092495
NCT00092495已完成3 期

A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine

Merck Sharp & Dohme LLC0 个研究点目标入组 3,055 人开始时间: 2002年12月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
3,055
主要终点
Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3

研究概览

简要总结

The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
10 Years 至 23 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy adolescents and pre-adolescents with no prior sexual history
  • Healthy women who have an intact uterus with lifetime history of 0-4 sexual partners

排除标准

  • Prior Human Papillomavirus (HPV) vaccination
  • Prior abnormal Paps
  • Prior history of genital warts

结局指标

主要结局

Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3

时间窗: Week 4 Postdose 3 (Month 7)

Geometric Mean Titer (GMT) for HPV 16 by Week 4 Postdose 3

时间窗: Week 4 Postdose 3 (Month 7)

Geometric Mean Titer (GMT) for HPV 11 by Week 4 Postdose 3

时间窗: Week 4 Postdose 3 (Month 7)

Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3

时间窗: Week 4 Postdose 3 (Month 7)

Seroconversion is defined as going from seronegative to seropositive. Seropositivity is defined as an anti-HPV 6 titer ≥ 20 milliMerck units per milliliter (mMU/mL).

Number of Subjects Who Seroconverted for HPV 11 by Week 4 Postdose 3

时间窗: Week 4 Postdose 3 (Month 7)

Seroconversion is defined as going from seronegative to seropositive. Seropositivity is defined as an anti-HPV 11 titer ≥ 16 milliMerck units per milliliter (mMU/mL).

Number of Subjects Who Seroconverted for HPV 18 by Week 4 Postdose 3

时间窗: Week 4 Postdose 3 (Month 7)

Seroconversion is defined as going from seronegative to seropositive. Seropositivity is defined as an anti-HPV 18 titer ≥ 24 milliMerck units per milliliter (mMU/mL).

Geometric Mean Titer (GMT) for HPV 18 by Week 4 Postdose 3

时间窗: Week 4 Postdose 3 (Month 7)

Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3

时间窗: Week 4 Postdose 3 (Month 7)

Seropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL). Seroconversion is defined as going from seronegative to seropositive.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验